Skip to content

Prevalence of primary Sjögren's syndrome and acne inversa in premenopausal women with vaginal dryness at gynecological screening

Prevalence of primary Sjögren's syndrome and acne inversa in premenopausal women with vaginal dryness at gynecological screening - DryScreen

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00032477
Enrollment
10000
Registered
2023-10-05
Start date
2023-02-03
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M35.0

Interventions

Group 1: Screening Population The aim of our study is to determine the prevalence of primary Sjögren's syndrome in vaginal dryness. In a second step, clinical differences between patients with vaginal

Sponsors

Medizinische Hochschule Hannover
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: There must be a capacity to consent.

Exclusion criteria

Exclusion criteria: All patients who do not meet the inclusion criteria. Lack of Capacity to consent. Pregnancy or lactation, previous or current gynecologic cancer treatment, especially brachytherapy. Pre-existing acne inversa or primary Sjögren's syndrome.

Design outcomes

Primary

MeasureTime frame
Number of newly diagnosed patients with primary Sjögren's syndrome according to the 2016 ACR/EULAR classification criteria or number of newly diagnosed patients with acne inversa diagnosed by an expert.

Secondary

MeasureTime frame
Analysis of questionnaires, activity score ESSDAI score &ESSPRI score, Medical history questionnaire, Hidradenitis Suppurativa Clinical Response (HiSCR), vaginale health index (VHI) and Female Sexual Function Index (FSFI).

Countries

Germany

Contacts

Public ContactDiana Ernst

Medizinische Hochschule Hannover

ernst.diana@mh-hannover.de+49 511 532 5044

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026